Protein S100A8/A9: A Potential New Biomarker for Pancreatic Diseases
Standard
Protein S100A8/A9: A Potential New Biomarker for Pancreatic Diseases. / El Gammal, Alexander Tarek; Sturm, Jörn H.; Pinnschmidt, Hans; Hofmann, Bianca Thidahan; Bellon, Eugen; Ghadban, Tarik; Melling, Nathaniel Timon; Bachmann, Kai Alexander; Izbicki, Jakob; Bockhorn, Maximilian; Güngör, Cenap; Perez, Daniel.
In: Int J Clin Endocrinol Metab, Vol. 3, No. 1, 2017, p. 023-028.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Protein S100A8/A9: A Potential New Biomarker for Pancreatic Diseases
AU - El Gammal, Alexander Tarek
AU - Sturm, Jörn H.
AU - Pinnschmidt, Hans
AU - Hofmann, Bianca Thidahan
AU - Bellon, Eugen
AU - Ghadban, Tarik
AU - Melling, Nathaniel Timon
AU - Bachmann, Kai Alexander
AU - Izbicki, Jakob
AU - Bockhorn, Maximilian
AU - Güngör, Cenap
AU - Perez, Daniel
PY - 2017
Y1 - 2017
N2 - Objectives: S100A8/A9 expression has been linked to carcinogenesis and inflammation. We hypothesized that S100A8/A9 protein serum levels are a useful stratification marker for patients with pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or chronic pancreatitis (CP).Methods: S100A8/A9 serum levels were analysed in PDAC, CP and IPMN patients and compared to S100A8/A9 healthy donor controls (HD) using ELISA. S100A8/A9 levels and clinical data were statistically analysed.Results: Out of 134 patients included, 84 were diagnosed with PDAC (46%), 30 patients with IPMN (16%) and 20 patients with CP (11%), 50 patients were HD (27%). When compared to HD (343.3 ng/ml), S100A8/A9 serum concentration was elevated in PDAC (402.0 ng/ml, p = 0.001) and CP patients (426.51 ng/ml p < 0.001). Also, S100A8/A9 levels were elevated in PDAC compared to IPMN group (369.0 ng/ml p = 0.026) and in CP compared to IPMN group (p = 0.001). A multivariate model including age, gender, leukocyte levels, C-reactive protein (CrP), S100A8/A9 and CA 19-9 concentrations reported a diagnostic sensitivity of 74.8%.Conclusion: S100A8/A9 serum levels are increased in patients with PDAC, CP, and IPMN and might be useful to distinguish malignant and inflammatory diseases from normal and non-malignant pathological conditions.
AB - Objectives: S100A8/A9 expression has been linked to carcinogenesis and inflammation. We hypothesized that S100A8/A9 protein serum levels are a useful stratification marker for patients with pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or chronic pancreatitis (CP).Methods: S100A8/A9 serum levels were analysed in PDAC, CP and IPMN patients and compared to S100A8/A9 healthy donor controls (HD) using ELISA. S100A8/A9 levels and clinical data were statistically analysed.Results: Out of 134 patients included, 84 were diagnosed with PDAC (46%), 30 patients with IPMN (16%) and 20 patients with CP (11%), 50 patients were HD (27%). When compared to HD (343.3 ng/ml), S100A8/A9 serum concentration was elevated in PDAC (402.0 ng/ml, p = 0.001) and CP patients (426.51 ng/ml p < 0.001). Also, S100A8/A9 levels were elevated in PDAC compared to IPMN group (369.0 ng/ml p = 0.026) and in CP compared to IPMN group (p = 0.001). A multivariate model including age, gender, leukocyte levels, C-reactive protein (CrP), S100A8/A9 and CA 19-9 concentrations reported a diagnostic sensitivity of 74.8%.Conclusion: S100A8/A9 serum levels are increased in patients with PDAC, CP, and IPMN and might be useful to distinguish malignant and inflammatory diseases from normal and non-malignant pathological conditions.
M3 - SCORING: Journal article
VL - 3
SP - 23
EP - 28
JO - Int J Clin Endocrinol Metab
JF - Int J Clin Endocrinol Metab
SN - 1726-9148
IS - 1
ER -
